The SENTRY Trial: Selinexor Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

Prithviraj Bose, MD, and Pankit Vachhani, MD, provide an overview of the phase 3 SENTRY trial (NCT04562389) evaluating selinexor (Xpovio) plus ruxolitinib (Jakafi) vs placebo plus ruxolitnib in patients with JAK inhibitor–naive myelofibrosis. Bose outlines the study design, patient population, and rationale for combining these agents in the frontline setting. Vachhani discusses how this trial aims to determine whether combination therapy can improve spleen volume reduction and symptom outcomes compared with standard JAK inhibitor therapy alone.